Cipla gets EIR from USFDA for Kurkumbh facility
The Kurkumbh manufacturing facility was inspected by the United States Food and Drug Administration (USFDA) from March 11 to March 20, 2019, Cipla said in a BSE filing.
Cipla has received EIR from the US health regulator after inspection of Kurkumbh facility in Maharashtra, Photo: Reuters
Written By: PTI
Updated: Mon, Jun 10, 2019
06:38 pm
06:38 pm
New Delhi, PTI
Execution of Multiple Therapies led to robust growth in Q2: Kedar Upadhye, Global CFO, Cipla LimitedPharma major Cipla Monday said it has received establishment inspection report (EIR) from the US health regulator after inspection of Kurkumbh facility in Maharashtra.
The Kurkumbh manufacturing facility was inspected by the United States Food and Drug Administration (USFDA) from March 11 to March 20, 2019, Cipla said in a BSE filing.
The company has received the EIR indicating closure of the inspection, it added.
Shares of Cipla closed at Rs 553.70 per scrip on the BSE, up 0.75 per cent from its previous close.
Stocks in Focus on September 30: IRCTC, DHFL to RNAM; here are the 5 Newsmakers of the Day
Cipla is investing a lot on R&D; Clinical trial of Generic Advair’s is going on track: Kedar Upadhye
Stocks in Focus on July 22: Bosch, Dr Reddy’s to BHEL; here are the 5 Newsmakers of the Day
'10 ki Kamai': Should you buy Cipla shares? Expert gives this target